Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vaxcyte Inc PCVX

Healthcare Biotechnology
Vaxcyte Inc. is a clinical-stage vaccine company. It is engaged in developing a spectrum conjugate and protein vaccines to prevent or treat bacterial infectious diseases. Its lead candidate, VAX-24, is a Phase III-ready 24-valent, carrier-sparing pneumococcal conjugate vaccine (PCV) being developed for the prevention of invasive pneumococcal disease (IPD). VAX-31, the Company’s next generation... see more

Recent & Breaking News (NDAQ:PCVX)

Vaxcyte Provides Positive Regulatory Updates for VAX-24 Adult and Pediatric Programs

GlobeNewswire August 4, 2022

Vaxcyte Completes Enrollment of Phase 2 Portion of Phase 1/2 Clinical Proof-of-Concept Study Evaluating Safety, Tolerability and Immunogenicity of VAX-24 in Adults

GlobeNewswire July 12, 2022

Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)

PR Newswire June 27, 2022

Vaxcyte to Present at the Jefferies Healthcare Conference

GlobeNewswire June 2, 2022

Vaxcyte Reports First Quarter 2022 Financial Results and Provides Business Update

GlobeNewswire May 9, 2022

Vaxcyte to Participate in Upcoming Investor Conferences in May

GlobeNewswire May 3, 2022

Vaxcyte to Present at the 21st Annual Needham Virtual Healthcare Conference

GlobeNewswire April 5, 2022

Vaxcyte Doses First Participants in Phase 2 Portion of Ongoing VAX-24 Phase 1/2 Clinical Proof-of-Concept Study in Adults

GlobeNewswire April 4, 2022

Vaxcyte Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

GlobeNewswire February 28, 2022

Vaxcyte Doses First Participants in Phase 1/2 Clinical Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in Adults

GlobeNewswire February 23, 2022

Vaxcyte to Report Fourth Quarter and Full Year 2021 Financial Results on February 28, 2022

GlobeNewswire February 17, 2022

Vaxcyte to Present at the 11th Annual SVB Leerink Global Healthcare Conference

GlobeNewswire February 10, 2022

Athira Pharma Announces Appointment of Grant Pickering to its Board of Directors

GlobeNewswire January 31, 2022

Vaxcyte Announces Pricing of $100 Million Public Offering

GlobeNewswire January 13, 2022

Vaxcyte Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 12, 2022

Vaxcyte Announces FDA Clearance of Investigational New Drug Application for VAX-24 for the Prevention of Invasive Pneumococcal Disease

GlobeNewswire January 6, 2022

Vaxcyte to Present at Upcoming Investor Conferences

GlobeNewswire November 11, 2021

Vaxcyte Reports Third Quarter 2021 Financial Results and Provides Business Update

GlobeNewswire November 10, 2021

Vaxcyte Appoints Carlos Paya and Michael Kamarck to Its Board of Directors

GlobeNewswire October 28, 2021

Vaxcyte to Present at Guggenheim 2nd Annual Vaccine and Infectious Disease Conference

GlobeNewswire September 28, 2021